Cargando…
Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide–Drug Conjugate
[Image: see text] EphA2 overexpression has been associated with metastasis in multiple cancer types, including melanomas and ovarian, prostate, lung, and breast cancers. We have recently proposed the development of peptide–drug conjugates (PDCs) using agonistic EphA2-targeting agents, such as the YS...
Autores principales: | Salem, Ahmed F., Wang, Si, Billet, Sandrine, Chen, Jie-Fu, Udompholkul, Parima, Gambini, Luca, Baggio, Carlo, Tseng, Hsian-Rong, Posadas, Edwin M., Bhowmick, Neil A., Pellecchia, Maurizio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2018
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907794/ https://www.ncbi.nlm.nih.gov/pubmed/29470068 http://dx.doi.org/10.1021/acs.jmedchem.7b01837 |
Ejemplares similares
-
Therapeutic Targeting of Pancreatic Cancer via EphA2 Dimeric Agonistic Agents
por: Salem, Ahmed F., et al.
Publicado: (2020) -
Targefrin:
A Potent Agent Targeting the Ligand Binding
Domain of EphA2
por: Baggio, Carlo, et al.
Publicado: (2022) -
Effective Tumor Targeting by EphA2-Agonist-Biotin-Streptavidin Conjugates
por: Udompholkul, Parima, et al.
Publicado: (2021) -
Prostate Cancer Metastases Are Strongly Inhibited by Agonistic Epha2 Ligands in an Orthotopic Mouse Model
por: Salem, Ahmed F., et al.
Publicado: (2020) -
Mixture-Based Screening
of Focused Combinatorial Libraries
by NMR: Application to the Antiapoptotic Protein hMcl-1
por: Alboreggia, Giulia, et al.
Publicado: (2023)